or Try an Advanced Search...

    Technical Analysis for MDGL - Madrigal Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 236.16 4.73% 10.67
    MDGL closed up 4.73 percent on Friday, May 31, 2024, on 84 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical MDGL trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Crossed Above 50 DMA Bullish 0.00%
    Outside Day Range Expansion 0.00%
    50 DMA Resistance Bearish 4.73%
    NR7 Range Contraction 4.73%
    NR7-2 Range Contraction 4.73%
    Narrow Range Bar Range Contraction 4.73%
    Gapped Up Strength 4.73%
    20 DMA Support Bullish 6.13%
    NR7 Range Contraction 6.13%
    Older End-of-Day Signals for MDGL ...

       Recent Intraday Alerts

    Alert Time
    Up 3% 2 days ago
    60 Minute Opening Range Breakout 2 days ago
    Up 2% 2 days ago
    Rose Above 10 DMA 2 days ago
    20 DMA Support 2 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    MDGL Chart by TradingView
    Basic chart:

    Profile

    Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-' agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medication Lipid Endocrine System Metabolic Disease Cholesterol Thyroid Hypercholesterolemia Dyslipidemia Glands Triglyceride Cardiovascular And Metabolic Diseases Hyperlipidemia Vascular And Metabolic Diseases

    Is MDGL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 29 Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
    May 24 Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ...
    May 21 Is Madrigal Pharmaceuticals Stock a Buy?
    May 17 3 High Insider Ownership US Stocks With Up To 55% Revenue Growth
    May 16 John Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role
    May 8 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript
    May 8 Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
    May 7 Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript
    May 7 Madrigal sees ‘tremendous interest’ in new NASH drug Rezdiffra
    May 7 Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch
    See more MDGL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 299.98
    52 Week Low 119.7604
    Average Volume 412,669
    200-Day Moving Average 204.19
    50-Day Moving Average 228.37
    20-Day Moving Average 222.82
    10-Day Moving Average 230.16
    Average True Range 11.36
    RSI (14) 57.63
    ADX 16.41
    +DI 30.32
    -DI 19.38
    Chandelier Exit (Long, 3 ATRs) 216.27
    Chandelier Exit (Short, 3 ATRs) 234.15
    Upper Bollinger Bands 244.95
    Lower Bollinger Band 200.69
    Percent B (%b) 0.8
    BandWidth 19.87
    MACD Line 2.01
    MACD Signal Line 0.32
    MACD Histogram 1.6898
    Fundamentals Value
    Market Cap 4.66 Billion
    Num Shares 19.7 Million
    EPS -19.24
    Price-to-Earnings (P/E) Ratio -12.27
    Price-to-Sales 0.00
    Price-to-Book 168.57
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 258.43
    Resistance 3 (R3) 256.14 246.43 254.72
    Resistance 2 (R2) 246.43 240.76 247.57 253.48
    Resistance 1 (R1) 241.30 237.26 243.86 243.58 252.24
    Pivot Point 231.59 231.59 232.87 232.73 231.59
    Support 1 (S1) 226.45 225.91 229.02 228.74 220.08
    Support 2 (S2) 216.74 222.41 217.88 218.84
    Support 3 (S3) 211.61 216.74 217.60
    Support 4 (S4) 213.89